The complement drugs are targeting different parts of the complement pathways such as C5 inhibitors eculizumab and ravulizumab, C3 inhibitor (pegcetacoplan APL-2), C1 inhibitors, MASP 1 and MASP2 inhibitors, C5a inhibitors, and Complement Factor D inhibitors for a wide range of kidney diseases (44). The gene discussed is C5; the disease is kidney disorder.